doxorubicin

A group of researchers from the Center for Neuroscience and Cell Biology (CNC) at the University of Coimbra (UC), uncovered a new mechanism behind the cardiotoxicity of the anticancer drug Doxorubicin (or Adriamycin) that can be explored in the future as a new therapeutic target to counteract the adverse effects of chemotherapy. Although Doxorubicin is a powerful chemotherapeutic agent, it has severe long-term adverse effects that compromise the cardiac function of patients.

Authors and affiliations:

Tania Martins-Marques ^1,2, Maria Joao Pinho ^1,2, Monica Zuzarte ^1,2, Carla Oliveira ^3,4,5, Paulo Pereira ⁶, Joost P. G. Sluijter ^7,8, Celia Gomes ^2,9,10, Henrique Girao ^1,2*

¹Institute of Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Coimbra, Portugal;

²CNC.IBILI, University of Coimbra, Coimbra, Portugal; 

The work entitled «Differential effects of methoxyamine on doxorubicin cytotoxicity and genotoxicity in MDA-MB-231 human breast cancer cells» addresses the study of DNA repair inhibitors. These compounds have been developed as potential therapeutic agents for the enhancement of the chemotherapy efficacy. In this article, we assessed the effects of methoxyamine in the cytotoxicity and genotoxicity induced by doxorubicin in MDA-MB-231 breast cancer cells. Methoxyamine is an indirect inhibitor of APE1 enzyme involved in base excision repair (BER) pathway.